Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.600 -0.060 (-0.90%)
Streaming Delayed Price Updated: 11:42 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
41 42 Next >
News headline image
Psychedelic Stock Gainers And Losers From February 15, 2023 ↗
 
Via Benzinga
News headline image
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment ↗
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022. The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
Via Investor Brand Network
News headline image
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
News headline image
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
"Multi-Bagger" Portfolio Update ↗
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. I'm tracking 12 microcap stocks that might bounce back with major returns - dare I say 
Via Talk Markets
News headline image
Major Psychedelic Compound-Based Stocks UP 13% YTD ↗
We track the performance of the 6 largest companies researching the treatment of mental illnesses based on the use of one or more of 10 different psychedelic compound-based substances. 
Via Talk Markets
News headline image
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 8, 2023 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 7, 2023 ↗
 
Via Benzinga
News headline image
The "Multi-Bagger" Portfolio Continued To Outperform The S&P 500 Last Week ↗
Our basket of mostly microcap cannabis, psychedelic and plant-based food stocks was extremely oversold in 2022 but we're watching for them to bounce back in 2023. 
Via Talk Markets
News headline image
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
The 7 Most Promising Psychedelic Stocks to Buy in February ↗
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector. 
Via InvestorPlace
News headline image
6 Largest Psychedelic Stocks Down 3% This Week ↗
The six largest of the 40 companies researching the treatment of mental illnesses by using psychedelic substances, which constitute our Psychedelic Drug Stocks Index, are now up 13% YTD despite a loss... 
Via Talk Markets
News headline image
Psychedelic Stock Gainers And Losers From February 3, 2023 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 2, 2023 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 1, 2023 ↗
 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
News headline image
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment ↗
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated... 
Via Benzinga
News headline image
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
News headline image
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
The "Multi-Bagger" Portfolio Update: Week Ending January 27 ↗
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but many of them could possibly bounce back with major returns in 2023. We track the performance of a basket of 10 such... 
Via Talk Markets
News headline image
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD ↗
We track the 6 largest psychedelic stocks that research the treatment of mental illnesses based on the use of one or more psychedelic substances - weekly and YTD results. 
Via Talk Markets
News headline image
Cybin, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 26, 2023 ↗
 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Via Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.